Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
about
Influenza virus vaccines: lessons from the 2009 H1N1 pandemicH5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer modelLong-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccineExtended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritisLow seroconversion after one dose of AS03-adjuvanted H1N1 pandemic influenza vaccine in solid-organ transplant recipientsRefining the approach to vaccines against influenza A viruses with pandemic potential.Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled TrialLong-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine.Effectiveness of a MF-59™-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study.Strategies for successful rapid trials of influenza vaccine.Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines.Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients.New technologies for influenza vaccines.H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on studyDevelopment and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years.Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.Prospective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009-2010 using matched hospital and test-negative controlsImmunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older personsEvaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or olderPreflucel®: a Vero-cell culture-derived trivalent influenza vaccine.Pandemic influenza A (H1N1) 2009 vaccination in children: a UK perspective.Multi-centre observational study of transplacental transmission of influenza antibodies following vaccination with AS03(A)-adjuvanted H1N1 2009 vaccineSafety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort studyVero cell culture-derived pandemic influenza vaccines: preclinical and clinical development.Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccinesIs rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis.Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques.Return of inactivated whole-virus vaccine for superior efficacy.Assessing the safety of influenza vaccination in specific populations: children and the elderly.Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice.Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.Respirators versus medical masks: evidence accumulates but the jury remains out.The safety of H1N1 vaccine in children in Saudi Arabia: a cohort study using modern technology in a developing country.
P2860
Q27027029-9CD663AB-08E3-4F55-BAB3-6746DFFE30E6Q28741304-B1E4406D-60EA-4085-B9DB-FCFA2141D5ACQ30353329-0F2A5C52-779A-4E0A-88BA-8C4A4F5927D7Q30353675-9CB262E8-5426-458F-8C0F-2489BC3676CAQ30357450-9D192720-65B8-4ECA-84E3-3540A3816ADEQ30357871-6AA5D367-A1ED-4CC7-B0A9-DC7D16F76334Q30381595-25B215E4-8211-41E5-963C-409AA02D5513Q30394896-9FC85F40-FEB8-4DDD-A756-4403F5E8A634Q30397652-4CE54CA6-AB2A-413B-985A-60C117E70A99Q30401398-CC557BA3-631F-4A7D-A93F-920DC850E5D4Q30403361-4C0429DE-0D43-418D-85D0-3DB15BFD4829Q30404358-15BCFC3C-4B9A-429C-8B20-1CE625ACC180Q30404989-A2208E79-A160-47F6-95D2-157E191F44C6Q30406834-9AD74489-4B2E-465A-9EB4-EEEB538D6CC2Q30407050-A730C551-435F-4445-A046-D731B38135F2Q30409595-18B43FBF-4161-4ACF-988E-00559553FA57Q30411859-C1B3C42D-F56D-4E40-A12A-2E2E2CDFCA61Q30412103-93C046BB-DB03-447B-92DE-F2AE8D541D0FQ30413695-8465B748-3A6C-4933-9B26-F898ED25EB95Q30414384-70FBA6C6-DC88-4349-B0EC-D8351C3F3EA3Q30415263-4E01C42B-A77F-4582-BA0B-C99F543418BFQ30417245-8639CEFA-CF59-483B-905D-269628E0E383Q30417417-8B4E2B82-C065-452D-9D0F-6E869CFF4BF3Q30419062-062D746D-402F-43BF-B613-5D0659F4A29DQ30419943-DF90AB36-5770-466E-A4BA-98C6C505C94DQ30420569-1DD01DEA-BC42-421D-8BF4-0AE72D6BE60FQ30424939-6DCC5D96-0BA8-43FF-90DE-F88387692EEBQ30426674-7A66D945-EAC1-45FF-AFFA-D73FA0D64B0DQ30426869-64FAFA52-9A31-41AD-901B-E534B32B5589Q30429058-36281BC1-D6C7-4474-B659-0EE1C6C4A917Q30429185-0C40BEE5-4EEA-488F-A755-F4FEC2F71A06Q34274845-73243F00-9BB1-4B92-9A35-63F091104A74Q36367842-54F3018B-4F4A-49E6-A2C4-E2A97C4F6625Q37643792-D3252E78-F71F-466B-9DE7-2FC0838C1006Q37918307-783D66C9-FF43-43A0-812F-4DF0C35134D1Q38045920-EE481604-4D82-42AA-9D65-C2C1518027ACQ39262114-6162721D-1D06-4A1C-8637-B4A956A9ED5FQ40180898-4C48E47E-701B-4E4D-B74B-B648802FA55DQ42425287-2DCB15CC-FC35-458B-A4F8-DCB0B70878F0Q43171845-539F09BD-DC56-426A-96AC-56231F604C9B
P2860
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Immunogenicity and safety of a ...... tratified, head-to-head trial.
@ast
Immunogenicity and safety of a ...... tratified, head-to-head trial.
@en
type
label
Immunogenicity and safety of a ...... tratified, head-to-head trial.
@ast
Immunogenicity and safety of a ...... tratified, head-to-head trial.
@en
prefLabel
Immunogenicity and safety of a ...... tratified, head-to-head trial.
@ast
Immunogenicity and safety of a ...... tratified, head-to-head trial.
@en
P2093
P50
P1476
Immunogenicity and safety of a ...... tratified, head-to-head trial.
@en
P2093
Fiona C Warren
Karl G Nicholson
Katja Hoschler
Maria Zambon
Marie-Jo Medina
Tristan W Clark
P304
P356
10.1016/S1473-3099(10)70296-6
P577
2010-12-16T00:00:00Z